Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCENTAGE-B

77.450
-1.900-2.39%
Volume:6.08M
Turnover:470.60M
Market Cap:26.97B
PE:-52.71
High:81.300
Open:79.950
Low:75.000
Close:79.350
Loading ...

Company Profile

Company Name:
ASCENTAGE-B
Exchange:
SEHK
Establishment Date:
2009
Employees:
567
Office Location:
Suzhou Industrial Park,68 Xinqing Road,Suzhou,Jiangsu Province,China
Zip Code:
215000
Fax:
- -
Introduction:
Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.

Directors

Name
Position
Dajun Yang
Chairman, Chief Executive Officer and Director
Changqing Ye
Director
David Sidransky
Director
Debra Yu
Director
Marc E. Lippman
Director
Marina S. Bozilenko
Director
Shaomeng Wang
Director
Simon Dazhong Lu
Director
Wei Ren
Director

Shareholders

Name
Position
Dajun Yang
Chairman, Chief Executive Officer and Director
Thomas J. Knapp
Senior Vice President, General Counsel
Jin Cao
Head of Finance
Raymond Jeffrey Kmetz
Chief Business Officer
Yifan Zhai
Chief Medical Officer